share_log

EyePoint Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144

EyePoint Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144

EyePoint Pharmaceuticals | 144：擬議出售證券
美股sec公告 ·  05/14 16:46
Moomoo AI 已提取核心訊息
EyePoint Pharmaceuticals, Inc. Director David R. Guyer is set to sell 71,850 shares of common stock on 05/14/2024, as announced in a recent filing. The shares, valued at an aggregate market value of $897,407, were acquired through a series of Restricted Stock Unit (RSU) vestings and a stock option exercise. The RSUs vested on three separate occasions: 1,900 shares on 02/28/2021, 2,500 shares on 06/22/2022, and 3,000 shares on 02/09/2023, all as part of compensation from the issuer. Additionally, 64,450 shares were obtained through a stock option exercise on 05/14/2024, paid for with cash. The planned sale follows a period where no securities transactions were reported in the past three months. The notice of the intended sale was filed on the same date as the sale, with the plan for the transaction having been adopted earlier on 01/25/2024.
EyePoint Pharmaceuticals, Inc. Director David R. Guyer is set to sell 71,850 shares of common stock on 05/14/2024, as announced in a recent filing. The shares, valued at an aggregate market value of $897,407, were acquired through a series of Restricted Stock Unit (RSU) vestings and a stock option exercise. The RSUs vested on three separate occasions: 1,900 shares on 02/28/2021, 2,500 shares on 06/22/2022, and 3,000 shares on 02/09/2023, all as part of compensation from the issuer. Additionally, 64,450 shares were obtained through a stock option exercise on 05/14/2024, paid for with cash. The planned sale follows a period where no securities transactions were reported in the past three months. The notice of the intended sale was filed on the same date as the sale, with the plan for the transaction having been adopted earlier on 01/25/2024.
正如在最近的一份文件中宣佈的那樣，EyePoint Pharmicals, Inc.董事戴維·蓋爾定於2024年5月14日出售71,850股普通股。這些股票的總市值爲897,407美元，是通過一系列限制性股票單位（RSU）歸屬和股票期權行使收購的。限制性股票單位在三個不同的場合歸屬：2021年2月28日歸屬於1,900股，2022年6月22日歸屬於2,500股，2023年9月2日歸屬於3,000股，全部作爲發行人薪酬的一部分。此外，2024年5月14日通過股票期權行使獲得了64,450股股票，以現金支付。計劃中的出售是在過去三個月中沒有報告任何證券交易之後進行的。擬出售通知與出售的同一天提交，交易計劃已於2024年1月25日早些時候通過。
正如在最近的一份文件中宣佈的那樣，EyePoint Pharmicals, Inc.董事戴維·蓋爾定於2024年5月14日出售71,850股普通股。這些股票的總市值爲897,407美元，是通過一系列限制性股票單位（RSU）歸屬和股票期權行使收購的。限制性股票單位在三個不同的場合歸屬：2021年2月28日歸屬於1,900股，2022年6月22日歸屬於2,500股，2023年9月2日歸屬於3,000股，全部作爲發行人薪酬的一部分。此外，2024年5月14日通過股票期權行使獲得了64,450股股票，以現金支付。計劃中的出售是在過去三個月中沒有報告任何證券交易之後進行的。擬出售通知與出售的同一天提交，交易計劃已於2024年1月25日早些時候通過。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息